Mylan acquires Merck KGaA's eastern European generics businesses
US pharma company Mylan has acquired Merck KGaA's Central & Eastern Europe (CEE) generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic.
US pharma company Mylan has acquired Merck KGaA's Central & Eastern Europe (CEE) generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic.
Mylan exercised its option to acquire these businesses as part of the original agreement signed in October 2007, in which Mylan acquired Merck KGaA's generics business (Merck Generics) in Western Europe, Asia-Pacific, Africa and North America.
"Our acquisition of the CEE businesses gives us access to an additional area with significant growth opportunities for generics," said Mylan vice chairman and ceo Robert J. Coury.
"It reflects our global strategy to leverage existing platforms, rather than create start-up organisations. In that respect, we believe the CEE businesses will benefit significantly from Mylan's scale, vertical and horizontal integration, and robust product portfolio."